ARQT - CIK 0001787306
Arcutis Biotherapeutics, Inc. (ARQT) reported net income of -$16.14M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$16.14M | +88.5% |
| FY 2024 | -$140.04M | +46.6% |
| FY 2023 | -$262.14M | +15.8% |
| FY 2022 | -$311.46M | -50.9% |
| FY 2021 | -$206.36M | -52.1% |
| FY 2020 | -$135.68M | -223.1% |
| FY 2019 | -$42.00M | -118.1% |
| FY 2018 | -$19.25M | - |
Arcutis Biotherapeutics, Inc. (ARQT) reported net income of -$16.14M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Arcutis Biotherapeutics, Inc.'s net income grew from -$19.25M to -$16.14M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.